









Markets
/
Stocks
/
nasdaq-rckt
/

Rocket Pharmaceuticals Inc

RCKT

3.170USD

+0.140+4.62%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

341.99MMarket Cap

LossP/E TTM



Rocket Pharmaceuticals Inc

3.170

+0.140+4.62%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance, the company shows strong fundamentals and technicals, which don't support the current strong trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

144 / 506

Overall Ranking

260 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 17 analysts

Buy

Current Rating

7.923

Target Price

+161.49%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 16.62.

Overvalued

The company’s latest PE is -1.27, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 101.52M shares, decreasing 12.89% quarter-over-quarter.

Held by Lee Ainslie

Star Investor Lee Ainslie holds 8.36M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.90.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 5.45, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.21, which is 313.72% below the recent high of -5.01 and -463.98% above the recent low of -6.83.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 144/506

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 7.29, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Rocket Pharmaceuticals Inc is 8.00, with a high of 16.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.29

Change

Support & Resistance

No Data

Analyst Rating

Based on 17 analysts

Buy

Current Rating

7.923

Target Price

+161.49%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Rocket Pharmaceuticals Inc

RCKT

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 5.24, which is lower than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 3.74 and the support level at 2.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.24

Change

0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.049

Neutral

RSI(14)

48.103

Neutral

STOCH(KDJ)(9,3,3)

37.786

Neutral

ATR(14)

0.155

High Vlolatility

CCI(14)

-146.226

Sell

Williams %R

62.039

Sell

TRIX(12,20)

0.002

Sell

StochRSI(14)

70.428

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.166

Buy

MA10

3.204

Sell

MA20

3.304

Sell

MA50

3.172

Sell

MA100

3.808

Sell

MA200

6.805

Sell

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 94.23%, representing a quarter-over-quarter decrease of 11.47%. The largest institutional shareholder is Lee Ainslie, holding a total of 8.36M shares, representing 7.75% of shares outstanding, with 58.48% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

17.69M

Maverick Capital, Ltd.

Star Investors

5.55M

+6.69%

BlackRock Institutional Trust Company, N.A.

6.15M

+9.13%

The Vanguard Group, Inc.

Star Investors

6.60M

+0.61%

Suvretta Capital Management, LLC

3.50M

+36.43%

MPM BioImpact LLC

1.62M

+58.57%

Geode Capital Management, L.L.C.

1.99M

+13.75%

Morgan Stanley & Co. LLC

1.78M

+125.66%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 2.98, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.